Cancer Research UK Trading Limited
Private Limited Company · London
ActiveUnited KingdomIncorporated 2002Private Limited Company
Financial position
Accounts to 2026-03-31 · GBP · Company accounts
Net assets
£324,000
Cash
£549,000
Turnover
£38,201,000
Profit / loss
—
Current assets
£9,258,000
Creditors < 1 year
£9,800,000
Equity
£324,000
Average employees
Not available
Balance-sheet trend
GBP · companyFinancial statements
Selected figures from the best-ranked available filing for each period. Missing values remain unknown.
Some figures were read by AI from scanned accounts, so small errors are possible. View the filed accounts
| Reported figures | 2026-03-31Company · AI-read | 2025-03-31Company · AI-read |
|---|---|---|
| Balance sheet | ||
| Net assets | £324,000 | £676,000 |
| Equity | £324,000 | £676,000 |
| Share capital | £2 | £2 |
| Retained earnings | £324,000 | £676,000 |
| Assets | ||
| Fixed assets | £866,000 | £897,000 |
| Property, plant & equipment | £866,000 | £897,000 |
| Current assets | £9,258,000 | £10,851,000 |
| Cash at bank | £549,000 | £471,000 |
| Debtors | £2,638,000 | £2,017,000 |
| Stock | £6,071,000 | £8,363,000 |
| Liabilities | ||
| Creditors within one year | £9,800,000 | £11,072,000 |
| Net current assets | −£542,000 | −£221,000 |
| Assets less current liabilities | £324,000 | £676,000 |
| Profit & loss | ||
| Turnover | £38,201,000 | £33,969,000 |
| Administrative expenses | £302,000 | £221,000 |
| Operating costs | ||
| Depreciation | £233,000 | £191,000 |
| Audit fees | £10,000 | £10,000 |
| People & pay | ||
| Staff costs | £7,314,000 | £7,149,000 |
| Wages & salaries | £6,600,000 | £6,557,000 |
| Social security costs | £456,000 | £340,000 |
| Pension costs | £258,000 | £252,000 |
| Source evidence | View filing | View filing |
From the accounts
What the accounts for 2026-03-31 say about themselves, read by AI from the scanned filing.
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Clean (unmodified)
- Immediate parent
- Cancer Research UK
- Ultimate parent
- Cancer Research UK
- Ultimate controlling party
- Cancer Research UK
- Accounts
- FRS 102
- Approved
- 2026-07-06, signed by Matthew Lynn
Turnover by segment (8)
- Bought in goods: 19,665 (000s) (2026-03-31)
- Bought in goods: 18,336 (000s) (2025-03-31)
- Event income (including event sponsorship and merchandise): 9,236 (000s) (2026-03-31)
- Event income (including event sponsorship and merchandise): 9,350 (000s) (2025-03-31)
- Royalty and commercial income: 8,293 (000s) (2026-03-31)
- Royalty and commercial income: 5,341 (000s) (2025-03-31)
- Commission from sale of goods sold on an agency basis: 1,007 (000s) (2026-03-31)
- Commission from sale of goods sold on an agency basis: 942 (000s) (2025-03-31)
Borrowings (2)
- Amounts owed to group undertakings · 2,183 (000s) · interest free · no fixed date of repayment and are repayable on demand · secured on unsecured
- Amounts owed to group undertakings · 4,875 (000s) · interest free · no fixed date of repayment and are repayable on demand · secured on unsecured
Share classes (2)
- 2 ordinary shares of £1 each
- 2 ordinary shares of £1 each
Contingent liabilities (1)
- The Company is party to a Group registration for VAT purposes and is jointly and severally liable for any VAT liabilities of the companies that are part of the same VAT registration.
Secured borrowing
Registered charges, lenders and security interests.
Charges and related records
0 outstanding chargesNo charges available in our records.